Journal of Sex & Marital Therapy · 2007 · 36 citations · 27 references
MedicinePharmacologyPsychiatryClinical PharmacologyPharmacogeneticsPsychopharmacologyMetabolic EvaluationMetabolic SyndromeSex Differences In HealthSex-based Pharmacokinetic DifferencesSexual DysfunctionSexual HealthCyp2d6 Drug MetabolismCyp2d6 GenotypeCyp2d6 GenotypingCyp2d6 PharmacogeneticsCyp2d6 PhenotypingCyp450-mediated InteractionsMale Sexual DysfunctionTherapeutic Efficacy Assessment
The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impression-Severity of Illness Scale (CGIS) and Arizona Sexual Experience Scale (ASEX). The phenotype procedure showed 7 males and 12 females with extensive metabolic status (EM) and 10 males and 26 females with poor metabolic status (PM). No variation in therapeutic efficacy between male and female subjects classified as PM and those marked as EM was found. A significantly higher rate of sexual dysfunction (p = 0.01) was recorded among females with a PM phenotype.
27
Pharmacogenetics of Antidepressant Medication Intolerance
Greer M. Murphy, C.M.E. Kremer, Heidi E. Rodrigues et al. · American Journal of Psychiatry · 2003 · 282 citations